1887

Abstract

Human respiratory syncytial virus (HRSV) is an important respiratory pathogen causing a spectrum of illness, from common cold-like symptoms, to bronchiolitis and pneumonia requiring hospitalization in infants, the immunocompromised and the elderly. HRSV exists as two antigenic subtypes, A and B, which typically cycle biannually in separate seasons. There are many unresolved questions in HRSV biology regarding the interactions and interplay of the two subtypes. Therefore, we generated a reverse genetics system for a subtype A HRSV from the 2011 season (A11) to complement our existing subtype B reverse genetics system. We obtained the sequence (HRSV) directly from an unpassaged clinical sample and generated the recombinant (r) HRSV. A version of the virus expressing enhanced green fluorescent protein (EGFP) from an additional transcription unit in the fifth (5) position of the genome, rHRSVEGFP(5), was also generated. rHRSV and rHRSVEGFP(5) grew comparably in cell culture. To facilitate animal co-infection studies, we derivatized our subtype B clinical isolate using reverse genetics toexpress the red fluorescent protein (dTom)-expressing rHRSVdTom(5). These viruses were then used to study simultaneous co-infection of the respiratory tract. Following intranasal infection, both rHRSVEGFP(5) and rHRSVdTom(5) infected cotton rats targeting the same cell populations and demonstrating that co-infection occurs . The implications of this finding on viral evolution are important since it shows that inter-subtype cooperativity and/or competition is feasible during the natural course of the infection.

Funding
This study was supported by the:
  • Paul Duprex , Medical Research Council , (Award G0801001)
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001471
2020-07-29
2020-12-03
Loading full text...

Full text loading...

References

  1. Collins P L, Karron RA et al. Respiratory syncytial virus and metapneumovirus. Knipe DM, Howley PM, Cohen JI, Griffin DE, Lamb RA et al. (editors) Fields Virology, 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013
    [Google Scholar]
  2. Rima B, Collins P, Easton A, Fouchier R, Kurath G et al. ICTV virus taxonomy profile: Pneumoviridae. J Gen Virol 2017; 98:2912–2913 [CrossRef][PubMed]
    [Google Scholar]
  3. Rima B, Balkema-Buschmann A, Dundon WG, Duprex P, Easton A et al. ICTV Virus Taxonomy Profile: Paramyxoviridae . J Gen Virol 2019; 100:1593–1594 [CrossRef][PubMed]
    [Google Scholar]
  4. Borchers AT, Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus--a comprehensive review. Clin Rev Allergy Immunol 2013; 45:331–379 [CrossRef][PubMed]
    [Google Scholar]
  5. Habibi MS, Jozwik A, Makris S, Dunning J, Paras A et al. Impaired antibody-mediated protection and defective IgA B-cell memory in experimental infection of adults with respiratory syncytial virus. Am J Respir Crit Care Med 2015; 191:1040–1049 [CrossRef][PubMed]
    [Google Scholar]
  6. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991; 163:693–698 [CrossRef][PubMed]
    [Google Scholar]
  7. Openshaw PJM, Chiu C, Culley FJ, Johansson C. Protective and harmful immunity to RSV infection. Annu Rev Immunol 2017; 35:501–532 [CrossRef][PubMed]
    [Google Scholar]
  8. Mazur NI, Higgins D, Nunes MC, Melero JA, Langedijk AC et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis 2018; 18:e295–e311 [CrossRef][PubMed]
    [Google Scholar]
  9. Simões EAF, DeVincenzo JP, Boeckh M, Bont L, Crowe JE et al. Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis 2015; 211 Suppl 1:S1–S20 [CrossRef][PubMed]
    [Google Scholar]
  10. Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 2011; 239:149–166 [CrossRef][PubMed]
    [Google Scholar]
  11. Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sánchez PJ et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 1998; 17:110–115 [CrossRef][PubMed]
    [Google Scholar]
  12. Hall CB, Walsh EE, Hruska JF, Betts RF, Hall WJ. Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults. JAMA 1983; 249:2666–2670[PubMed]
    [Google Scholar]
  13. Ison MG. Antiviral treatments. Clin Chest Med 2017; 38:139–153 [CrossRef][PubMed]
    [Google Scholar]
  14. Randolph AG, Wang EE. Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview. Arch Pediatr Adolesc Med 1996; 150:942–947 [CrossRef][PubMed]
    [Google Scholar]
  15. Anderson LJ, Hierholzer JC, Tsou C, Hendry RM, Fernie BF et al. Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis 1985; 151:626–633 [CrossRef][PubMed]
    [Google Scholar]
  16. Mufson MA, Orvell C, Rafnar B, Norrby E. Two distinct subtypes of human respiratory syncytial virus. J Gen Virol 1985; 66 (Pt 10:2111–2124 [CrossRef][PubMed]
    [Google Scholar]
  17. Hall CB, Walsh EE, Schnabel KC, Long CE, McConnochie KM et al. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J Infect Dis 1990; 162:1283–1290 [CrossRef][PubMed]
    [Google Scholar]
  18. Walsh EE, McConnochie KM, Long CE, Hall CB. Severity of respiratory syncytial virus infection is related to virus strain. J Infect Dis 1997; 175:814–820 [CrossRef][PubMed]
    [Google Scholar]
  19. Coggins WB, Lefkowitz EJ, Sullender WM. Genetic variability among group A and group B respiratory syncytial viruses in a children's Hospital. J Clin Microbiol 1998; 36:3552–3557 [CrossRef][PubMed]
    [Google Scholar]
  20. Peret TC, Hall CB, Schnabel KC, Golub JA, Anderson LJ. Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. J Gen Virol 1998; 79:2221–2229 [CrossRef][PubMed]
    [Google Scholar]
  21. Sullender WM, Sun L, Anderson LJ. Analysis of respiratory syncytial virus genetic variability with amplified cDNAs. J Clin Microbiol 1993; 31:1224–1231 [CrossRef][PubMed]
    [Google Scholar]
  22. Tan L, Coenjaerts FEJ, Houspie L, Viveen MC, van Bleek GM et al. The comparative genomics of human respiratory syncytial virus subgroups A and B: genetic variability and molecular evolutionary dynamics. J Virol 2013; 87:8213–8226 [CrossRef][PubMed]
    [Google Scholar]
  23. Johnson PR, Spriggs MK, Olmsted RA, Collins PL. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci U S A 1987; 84:5625–5629 [CrossRef]
    [Google Scholar]
  24. Peret TC, Hall CB, Hammond GW, Piedra PA, Storch GA et al. Circulation patterns of group A and B human respiratory syncytial virus genotypes in 5 communities in North America. J Infect Dis 2000; 181:1891–1896 [CrossRef][PubMed]
    [Google Scholar]
  25. Bouzas ML, Oliveira JR, Fukutani KF, Borges IC, Barral A et al. Respiratory syncytial virus A and B display different temporal patterns in a 4-year prospective cross-sectional study among children with acute respiratory infection in a tropical City. Medicine 2016; 95:e5142 [CrossRef][PubMed]
    [Google Scholar]
  26. White LJ, Waris M, Cane PA, Nokes DJ, Medley GF. The transmission dynamics of groups A and B human respiratory syncytial virus (hRSV) in England & Wales and Finland: seasonality and cross-protection. Epidemiol Infect 2005; 133:279–289 [CrossRef][PubMed]
    [Google Scholar]
  27. Schobel SA, Stucker KM, Moore ML, Anderson LJ, Larkin EK et al. Respiratory syncytial virus whole-genome sequencing identifies convergent evolution of sequence duplication in the C-terminus of the G gene. Sci Rep 2016; 6:26311 [CrossRef][PubMed]
    [Google Scholar]
  28. Collins PL, Hill MG, Camargo E, Grosfeld H, Chanock RM et al. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci U S A 1995; 92:11563–11567 [CrossRef]
    [Google Scholar]
  29. Moore ML, Chi MH, Luongo C, Lukacs NW, Polosukhin VV et al. A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J Virol 2009; 83:4185–4194 [CrossRef][PubMed]
    [Google Scholar]
  30. Sacco RE, Durbin RK, Durbin JE. Animal models of respiratory syncytial virus infection and disease. Curr Opin Virol 2015; 13:117–122 [CrossRef][PubMed]
    [Google Scholar]
  31. Cormier SA, You D, Honnegowda S. The use of a neonatal mouse model to study respiratory syncytial virus infections. Expert Rev Anti Infect Ther 2010; 8:1371–1380 [CrossRef][PubMed]
    [Google Scholar]
  32. Stark JM, McDowell SA, Koenigsknecht V, Prows DR, Leikauf JE et al. Genetic susceptibility to respiratory syncytial virus infection in inbred mice. J Med Virol 2002; 67:92–100 [CrossRef][PubMed]
    [Google Scholar]
  33. Moore EC, Barber J, Tripp RA. Respiratory syncytial virus (RSV) attachment and nonstructural proteins modify the type I interferon response associated with suppressor of cytokine signaling (SOCS) proteins and IFN-stimulated gene-15 (ISG15). Virol J 2008; 5:116 [CrossRef][PubMed]
    [Google Scholar]
  34. Altamirano-Lagos MJ, Díaz FE, Mansilla MA, Rivera-Pérez D, Soto D et al. Current animal models for understanding the pathology caused by the respiratory syncytial virus. Front Microbiol 2019; 10:873 [CrossRef][PubMed]
    [Google Scholar]
  35. Boukhvalova MS, Prince GA, Blanco JCG. The cotton rat model of respiratory viral infections. Biologicals 2009; 37:152–159 [CrossRef][PubMed]
    [Google Scholar]
  36. Blanco JCG, Pletneva LM, Oue RO, Patel MC, Boukhvalova MS. Maternal transfer of RSV immunity in cotton rats vaccinated during pregnancy. Vaccine 2015; 33:5371–5379 [CrossRef][PubMed]
    [Google Scholar]
  37. Bridgen A. Reverse genetics of RNA viruses. In Bridgen A. editor , 1st ed. Chichester, UK: John Wiley & Sons, Ltd; 2013
  38. Conzelmann KK. Reverse genetics of mononegavirales. Curr Top Microbiol Immunol 2004; 283:1–41 [CrossRef][PubMed]
    [Google Scholar]
  39. Corry J, Johnson SM, Cornwell J, Peeples ME. Preventing cleavage of the respiratory syncytial virus attachment protein in Vero cells rescues the infectivity of progeny virus for primary human airway cultures. J Virol 2016; 90:1311–1320 [CrossRef][PubMed]
    [Google Scholar]
  40. Hotard AL, Laikhter E, Brooks K, Hartert TV, Moore ML. Functional analysis of the 60-Nucleotide duplication in the respiratory syncytial virus Buenos Aires strain attachment glycoprotein. J Virol 2015; 89:8258–8266 [CrossRef][PubMed]
    [Google Scholar]
  41. Le Nouën C, McCarty T, Brown M, Smith ML, Lleras R et al. Genetic stability of genome-scale deoptimized RNA virus vaccine candidates under selective pressure. Proc Natl Acad Sci U S A 2017; 114:E386–E395 [CrossRef][PubMed]
    [Google Scholar]
  42. Rostad CA, Stobart CC, Gilbert BE, Pickles RJ, Hotard AL et al. A recombinant respiratory syncytial virus vaccine candidate attenuated by a Low-Fusion F protein is immunogenic and protective against challenge in cotton rats. J Virol 2016; 90:7508–7518 [CrossRef][PubMed]
    [Google Scholar]
  43. Lemon K, Nguyen DT, Ludlow M, Rennick LJ, Yüksel S et al. Recombinant subgroup B human respiratory syncytial virus expressing enhanced green fluorescent protein efficiently replicates in primary human cells and is virulent in cotton rats. J Virol 2015; 89:2849–2856 [CrossRef][PubMed]
    [Google Scholar]
  44. Kumaria R, Iyer LR, Hibberd ML, Simões EAF, Sugrue RJ. Whole genome characterization of non-tissue culture adapted HRSV strains in severely infected children. Virol J 2011; 8:372 [CrossRef][PubMed]
    [Google Scholar]
  45. Villenave R, O'Donoghue D, Thavagnanam S, Touzelet O, Skibinski G et al. Differential cytopathogenesis of respiratory syncytial virus prototypic and clinical isolates in primary pediatric bronchial epithelial cells. Virol J 2011; 8:43 [CrossRef][PubMed]
    [Google Scholar]
  46. Lemon K, Rima BK, McQuaid S, Allen IV, Duprex WP. The F gene of rodent brain-adapted mumps virus is a major determinant of neurovirulence. J Virol 2007; 81:8293–8302 [CrossRef][PubMed]
    [Google Scholar]
  47. Reed LJ, Muench H. A simple method for estimating fifty percent endpoints. AmJHyg 1938; 27:493–497
    [Google Scholar]
  48. Nguyen DT, de Vries RD, Ludlow M, van den Hoogen BG, Lemon K et al. Paramyxovirus infections in ex vivo lung slice cultures of different host species. J Virol Methods 2013; 193:159–165 [CrossRef][PubMed]
    [Google Scholar]
  49. Livet J, Weissman TA, Kang H, Draft RW, Lu J et al. Transgenic strategies for combinatorial expression of fluorescent proteins in the nervous system. Nature 2007; 450:56–62 [CrossRef][PubMed]
    [Google Scholar]
  50. Hoffman RM. The multiple uses of fluorescent proteins to visualize cancer in vivo . Nat Rev Cancer 2005; 5:796–806 [CrossRef][PubMed]
    [Google Scholar]
  51. de Vries RD, Ludlow M, de Jong A, Rennick LJ, Verburgh RJ et al. Delineating morbillivirus entry, dissemination and airborne transmission by studying in vivo competition of multicolor canine distemper viruses in ferrets. PLoS Pathog 2017; 13:e1006371 [CrossRef][PubMed]
    [Google Scholar]
  52. Emeny JM, Morgan MJ. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J Gen Virol 1979; 43:247–252 [CrossRef][PubMed]
    [Google Scholar]
  53. Hotard AL, Shaikh FY, Lee S, Yan D, Teng MN et al. A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology 2012; 434:129–136 [CrossRef][PubMed]
    [Google Scholar]
  54. Hu B, Jiang J, Zhan J, Li G, Jiang Y et al. Development of a reverse genetics system for respiratory syncytial virus long strain and an immunogenicity study of the recombinant virus. Virol J 2014; 11:142 [CrossRef][PubMed]
    [Google Scholar]
  55. Rameix-Welti M-A, Le Goffic R, Hervé P-L, Sourimant J, Rémot A et al. Visualizing the replication of respiratory syncytial virus in cells and in living mice. Nat Commun 2014; 5:5104 [CrossRef][PubMed]
    [Google Scholar]
  56. Jin H, Clarke D, Zhou HZ, Cheng X, Coelingh K et al. Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV. Virology 1998; 251:206–214 [CrossRef][PubMed]
    [Google Scholar]
  57. Perkins SM, Webb DL, Torrance SA, El Saleeby C, Harrison LM et al. Comparison of a real-time reverse transcriptase PCR assay and a culture technique for quantitative assessment of viral load in children naturally infected with respiratory syncytial virus. J Clin Microbiol 2005; 43:2356–2362 [CrossRef][PubMed]
    [Google Scholar]
  58. Vandini S, Biagi C, Lanari M. Respiratory syncytial virus: the influence of serotype and genotype variability on clinical course of infection. Int J Mol Sci 2017; 18:1717 [CrossRef][PubMed]
    [Google Scholar]
  59. Rijsbergen LC, Rennick LJ, Laksono BM, van Run PRWA, Kuiken T et al. In vivo comparison of a laboratory-adapted and clinical-isolate-based recombinant human respiratory syncytial virus. J Gen Virol 2020 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001471
Loading
/content/journal/jgv/10.1099/jgv.0.001471
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error